Vertex Pharmaceuticals | VRTX - Cost Of Sales

Stock Price
436.34
Daily Change
-10.44 -2.34%
Monthly
-11.38%
Yearly
-9.89%
Q2 Forecast
425.50

Vertex Pharmaceuticals reported $466M in Cost of Sales for its fiscal quarter ending in December of 2025.





Cost Of Sales Change Date
AbbVie USD 4.55B 757M Dec/2025
Acadia Pharmaceuticals USD 26.22M 4.58M Dec/2025
Agios Pharmaceuticals USD 1.88M 199K Dec/2025
Alnylam Pharmaceuticals USD 267.72M 67.57M Dec/2025
Amgen USD 1.79B 128M Dec/2025
Biogen USD 810.1M 205.1M Sep/2025
BioMarin Pharmaceutical USD 161.56M 16.62M Dec/2025
Bristol-Myers Squibb USD 4.92B 657M Dec/2025
Gilead Sciences USD 1.62B 50M Dec/2025
Incyte USD 121.18M 22.18M Dec/2025
Insmed USD 46.16M 15.25M Dec/2025
Ionis Pharmaceuticals USD 8M 5.66M Dec/2025
J&J USD 7.97B 689M Dec/2025
Merck USD 3.32B 531M Dec/2025
Moderna USD 452M 245M Dec/2025
Neurocrine Biosciences USD 17.6M 246.4M Dec/2025
Novartis USD 3.54B 3M Dec/2025
Pfizer USD 6.29B 2.12B Dec/2025
PTC Therapeutics USD 16.3M 7.02M Dec/2025
Puma Biotechnology USD 29.1M 18.44M Sep/2024
Regeneron Pharmaceuticals USD 584.6M 63M Dec/2025
Roche Holding CHF 8.48B 4.61B Dec/2025
Sangamo BioSciences 2.42M 1.11M Jun/2024
Sanofi EUR 4.29B 421M Dec/2025
Sarepta Therapeutics USD 399.38M 247.93M Dec/2025
Ultragenyx Pharmaceutical USD 29M 1.01M Dec/2025
United Therapeutics USD 474.7M 373.8M Dec/2025
Vertex Pharmaceuticals USD 466M 51.2M Dec/2025